Key result
Oral adjuncts with BMS match DES outcomes at lower cost in select patients.
Why the study?
High cost and prolonged DAPT requirements limit DES accessibility, prompting evaluation of systemic oral sirolimus, prednisone, and colchicine following BMS implantation as cost-effective alternatives.
Does the systemic administration of oral sirolimus, prednisone, or colchicine following bare-metal stent implantation provide comparable clinical outcomes and better cost-effectiveness compared to drug-eluting stents?
Does the systemic administration of oral sirolimus, prednisone, or colchicine following bare-metal stent implantation provide comparable clinical outcomes and better cost-effectiveness compared to drug-eluting stents?
Systemic administration of oral sirolimus, prednisone, or colchicine following bare-metal stent implantation may offer a cost-effective alternative to drug-eluting stents, particularly in resource-limited settings or when DES is contraindicated.
May warrant consideration in select patients where DES is unsuitable; leaves open confirmation of safety and optimal populations in larger trials.
Background: Coronary stenting remains the cornerstone of interventional cardiology. Drug-eluting stents (DES) have reduced restenosis compared to bare-metal stents (BMS), but their high cost and need for prolonged dual antiplatelet therapy (DAPT) limit accessibility in many regions. Recent evidence has revisited the potential role of systemic pharmacologic adjuncts—oral sirolimus (rapamycin), prednisone and colchicine—as cost-effective therapies to mitigate restenosis and adverse events following BMS implantation. Objective: This review critically evaluates the clinical and mechanistic evidence supporting the use of oral immunosuppressive or anti-inflammatory drugs following BMS implantation, with emphasis on their applicability in both resource-limited and general cardiology settings. Three randomized clinical trials comparing this strategy against DES are analyzed and discussed in this review. Conclusions: Oral sirolimus, prednisone, and colchicine demonstrate promising anti-inflammatory and antiproliferative effects that translate into clinical outcomes comparable to DES in a highly select population. Their systemic administration following BMS implantation may provide a feasible, cost-effective alternative where DES use is restricted by cost or clinical contraindications. Larger-scale, long-term trials are warranted to confirm safety, optimize dosing, and identify ideal patient populations for this “pharmacologic stent hybrid” strategy.
No takes yet. Share an insight, caveat, or question.
Fernández-Pereira et al. (2026) conducted a review in Coronary artery disease requiring stenting. Oral immunosuppressive or anti-inflammatory drugs (sirolimus, prednisone, colchicine) plus bare-metal stents vs. Drug-eluting stents (DES) was evaluated. Systemic administration of oral sirolimus, prednisone, or colchicine following bare-metal stent implantation provides clinical outcomes comparable to drug-eluting stents at a lower cost in highly select populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: